Endophenotypical drift in Huntington’s disease: a 5-year follow-up study

[11] Aylward EH(1997)CAG repeat number governs the development rate of pathology in Huntington’s disease Ann Neurol [Internet]. 251 935-107

[12] Wild EJ(2004)Cognitive changes in patients with Huntington’s disease (HD) and asymptomatic carriers of the HD mutation—a longitudinal follow-up study J Neurol [Internet]. 18 102-25

[13] Langbehn DR(2005)White matter volume and cognitive dysfunction in early Huntington’s disease Cogn Behav Neurol 4 15-192

[14] Long JD(2017)Common variant rs356182 near SNCA defines a Parkinson’s disease endophenotype Ann Clin Transl Neurol 52 178-1561

[15] Warner JH(2015)Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington’s disease Neurosci Biobehav Rev [Internet]. 29 1556-272

[16] Royall DR(2014)Systematic review of pharmacological treatments for depressive symptoms in Huntington’s disease Mov Disord 19 253-53

[17] Lauterbach EC(2010)Conceptual evolution in Alzheimer’s disease: Implications for understanding the clinical phenotype of progressive neurodegenerative disease J Alzheimer’s Dis 11 42-801

[18] Cummings JL(2012)Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data Lancet Neurol [Internet]. 8 791-42

[19] Reeve A(2009)Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data Lancet Neurol [Internet]. 10 31-458

[20] Rummans TA(2011)Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: The 12-month longitudinal analysis Lancet Neurol [Internet]. 1 1007-95

[11] Aylward EH(1997)CAG repeat number governs the development rate of pathology in Huntington’s disease Ann Neurol [Internet]. 251 935-107

[12] Wild EJ(2004)Cognitive changes in patients with Huntington’s disease (HD) and asymptomatic carriers of the HD mutation—a longitudinal follow-up study J Neurol [Internet]. 18 102-25

[13] Langbehn DR(2005)White matter volume and cognitive dysfunction in early Huntington’s disease Cogn Behav Neurol 4 15-192

[14] Long JD(2017)Common variant rs356182 near SNCA defines a Parkinson’s disease endophenotype Ann Clin Transl Neurol 52 178-1561

[15] Warner JH(2015)Environmental factors as modulators of neurodegeneration: insights from gene-environment interactions in Huntington’s disease Neurosci Biobehav Rev [Internet]. 29 1556-272

[16] Royall DR(2014)Systematic review of pharmacological treatments for depressive symptoms in Huntington’s disease Mov Disord 19 253-53

[17] Lauterbach EC(2010)Conceptual evolution in Alzheimer’s disease: Implications for understanding the clinical phenotype of progressive neurodegenerative disease J Alzheimer’s Dis 11 42-801

[18] Cummings JL(2012)Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data Lancet Neurol [Internet]. 8 791-42

[19] Reeve A(2009)Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data Lancet Neurol [Internet]. 10 31-458

[20] Rummans TA(2011)Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: The 12-month longitudinal analysis Lancet Neurol [Internet]. 1 1007-95